ViaCyte, Inc. (Formerly Known as Novocell, Inc.) To Present At 26th Annual Piper Jaffray Healthcare Conference
SAN DIEGO, Nov. 20, 2014 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of diabetes, today announced that Dr. Paul Laikind, President and Chief Executive Officer, will present at the 26th Annual Piper Jaffray Healthcare Conference as follows:
Tuesday, December 2, 2014
4:10 p.m. EST
The New York Palace, New York City
Dr. Laikind will review recent progress with the company's VC-01 islet replacement product candidate for the treatment of type 1 diabetes, which recently entered clinical phase testing. A Phase 1/2 trial to assess safety, tolerability, and efficacy of the product in human subjects with diabetes was launched in September 2014, and the first implant was announced in October 2014.
The presentation will be webcast live at the aforementioned time, and archived for viewing 90 days thereafter, via the Company's website at www.viacyte.com, under the News and Events Section.
ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes. ViaCyte's lead product candidate, the VC-01 combination product, is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells. These progenitor cells are implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. VC-01 is being developed as a potential long-term diabetes treatment without immune suppression, and without risk of hypoglycemia or other diabetes-related complications.
ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine and JDRF.